Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-001022
Filing Date
2025-02-14
Accepted
2025-02-14 17:00:38
Documents
66
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20241231x10q.htm   iXBRL 10-Q 1193008
2 EX-31.1 otlk-20241231xex31d1.htm EX-31.1 9723
3 EX-32.1 otlk-20241231xex32d1.htm EX-32.1 6377
  Complete submission text file 0001558370-25-001022.txt   6276747

Data Files

Seq Description Document Type Size
4 EX-101.SCH otlk-20241231.xsd EX-101.SCH 44091
5 EX-101.CAL otlk-20241231_cal.xml EX-101.CAL 41212
6 EX-101.DEF otlk-20241231_def.xml EX-101.DEF 194783
7 EX-101.LAB otlk-20241231_lab.xml EX-101.LAB 347305
8 EX-101.PRE otlk-20241231_pre.xml EX-101.PRE 322298
69 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20241231x10q_htm.xml XML 1128077
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 25630543
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)